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Abstract
In North America and Europe, the binary toxin 
positive Clostridium difficile strains of the ribotypes 
027 and 078 have been associated with death, 
toxic megacolon and other adverse outcomes. 
Following an increase in C. difficile infections 
(CDIs) in Queensland, a prevalence study involv-
ing 175 hospitals was undertaken in early 2012, 
identifying 168 cases of CDI over a 2 month 
period. Patient demographics and clinical char-
acteristics were recorded, and C. difficile isolates 
were ribotyped and tested for the presence of 
binary toxin genes. Most patients (106/168, 63.1%) 
were aged over 60 years. Overall, 98 (58.3%) 
developed symptoms after hospitalisation; 89 
cases (53.0%) developed symptoms more than 48 
hours after admission. Furthermore, 27 of the 62 
(67.7%) patients who developed symptoms in the 
community had been hospitalised within the last 3 
months. Thirteen of the 168 (7.7%) cases identified 
had severe disease, resulting in admission to the 
Intensive Care Unit or death within 30 days of the 
onset of symptoms. The 3 most common ribotypes 
isolated were UK 002 (22.9%), UK 014 (13.3%) 
and the binary toxin-positive ribotype UK 244 
(8.4%). The only other binary toxin positive ribotype 
isolated was UK 078 (n = 1). Of concern was the 
detection of the binary toxin positive ribotype UK 
244, which has recently been described in other 
parts of Australia and New Zealand. No isolates 
were of the international epidemic clone of ribotype 
UK 027, although ribotype UK 244 is genetically 
related to this clone. Further studies are required 
to track the epidemiology of ribotype UK 244 in 
Australia and New Zealand. Commun Dis Intell 
2014;38(4):E279–E284.
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Introduction
Clostridium difficile commonly causes infectious 
diarrhoea and is the main aetiological agent of 
pseudomembranous colitis.1 C. difficile strains 
of the ribotypes UK 027 and UK 078 have been 
associated with severe adverse outcomes such as 
toxic megacolon, colonic perforation, peritonitis, 
and increased mortality rates in North America 
and Europe.2 The hypervirulence of these strains 
has been attributed to the increased production 
of toxins A and B, as well as the presence of the 
binary toxin.3
Following the first report of local transmission of 
C. difficile ribotype UK 027 in Australia in 2009,4 a 
national laboratory survey was performed, but did 
not detect any strains of potentially hypervirulent 
ribotypes in Queensland (unpublished data, per-
sonal communication, T Riley). Between October 
2011 and early 2012, we observed an increase 
in C. difficile infections (CDI) in Queensland 
Health facilities using passive surveillance of 
diagnostic laboratory pathology results.5 Here we 
provide a more detailed state-wide snapshot of the 
epidemiology of hospital-identified CDI cases in 
Queensland in early 2012.
Methods
Study design and definitions
All Queensland public hospitals (n = 170) and 
5 private hospitals in Queensland, were invited 
and agreed to take part in the cross-sectional prev-
alence study. Between 10 April and 15 June 2012, 
patients aged over 2 years with diarrhoea at admis-
sion or during hospitalisation and testing positive 
for C. difficile were included in the study. The 
Australian definitions of hospital identified CDI6 
were used to identify cases, and classify recurrence 
and severe disease. A summary of these definitions 
are provided in Table 1. Patient samples collected 
during this time were cultured when available. 
C. difficile isolates were ribotyped and screened for 
the presence of the binary toxin in order to investi-
gate the prevalence of epidemic strains.
Surveillance data collection and analysis
Basic demographic and clinical data including 
data on patient location at onset of symptoms, 
history of recent hospitalisation and antibiotic use 
were collected by infection control practitioners on 
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a one page survey. Data were subsequently submit-
ted to the Centre for Healthcare Related Infection 
Surveillance and Prevention (CHRISP) and 
entered into a spreadsheet. CHRISP is the state-
wide unit responsible for overseeing healthcare 
associated infection surveillance, and prevention 
and control policy in Queensland public facili-
ties (www.health.qld.gov.au/chrisp). A follow-up 
survey was conducted 30 days after symptom 
onset to determine the prevalence of severe CDI 
using Australian surveillance guidelines (Table 1). 
De-identified data were imported into IBM SPSS 
version 20 for further descriptive analysis, includ-
ing chi-squared tests for differences in proportions.
Laboratory methods
C. difficile was cultured from stool specimens that 
tested C. difficile toxin positive by either polymer-
ase chain reaction (PCR) or enzyme immunoassay 
(EIA) at the referring laboratories. At the time 
of this snapshot a testing algorithm was in place 
across Queensland to ensure consistency in labora-
tory methods used. PCR ribotyping was performed 
as previously described.7,8 Briefly, genomic DNA 
was extracted from 24 hour horse blood agar 
cultures using the UltraClean Microbial DNA 
Isolation kit (MO BIO Laboratories Carlsbad, 
CA, United States) then PCR ribotyping was 
performed, using an ABI 3130 capillary sequencer 
(Applied Biosystems) with a GeneScan™ 1200 
LIZ® Size Standard (Applied Biosystems). The 
capillary sequencer data were uploaded to the 
Webribo database (http://webribo.ages.at/). UK 
ribotypes were determined for a representative 
of each Webribo ribotype, using the Anaerobe 
Reference Unit (Cardiff, UK) nomenclature 
where reference strains were available. This was 
done by comparing PCR products, concentrated 
using the Qiagen MinElute PCR purification 
kit, then separated using the QIAxcel capillary 
electrophoresis platform (Ambion Inc, Austin, 
Texas), to the UWA/PathWest reference library as 
previously described.10 The library consisted of 50 
UK ribotypes including 15 reference strains from 
the European Centre for Disease Prevention and 
Control and the most prevalent PCR ribotypes 
circulating in Australia. If a UK ribotype could 
not be assigned, local nomenclature (QX type) or 
webribo (WR type) nomenclature was assigned. 
Screening for binary toxins was performed as pre-
viously described.10
Ethics
This study was considered to be a quality assur-
ance audit by the Department.
In Queensland, the use of confidential patient 
information for audit is legislated under Section 
62H of the Health Services Act 1991. Approval 
was obtained from the Chief Health Officer of 
Queensland Health, and Chief Executive Officers 
of each private facility.
Ethical approval for this surveillance was not 
required as: surveillance of CDI in Queensland 
Health facilities is required in accordance with the 
Queensland Health Protocol for the Surveillance 
of Healthcare Associated Infection; private hos-
pitals in Queensland are required to undertake 
infection control surveillance in accordance with 
the Infection Control Standard of the Private 
Health Facilities Act 1999.
Results
Patient characteristics
During the audit period, a total of 168 CDI cases 
were identified. The patients ranged in age from 
3 to 100 years, with a median age of 68.5 years. 
A total of 36 cases were reported from private 
hospitals. Key descriptive variables such as age 
and location at onset of symptoms were compared 
using chi-square tests and did not significantly 
vary between private and public hospital patients 
so the data were combined. A summary of patient 
characteristics is shown in Table 1.
The majority of cases (98/168, 58%) developed 
symptoms following hospitalisation, however in 
nine of these patients, symptoms began within 
48 hours of admission. Five of the nine had a record 
of previous hospitalisation in the last month. Of 
the 62 cases that were community-onset, 27 (43%) 
had been admitted to a hospital in the previous 
month and 15 (24%) in the previous 1 to 3 months. 
Fifteen (9%) of the CDI cases were admitted from 
a residential or long term care facility (R/LTCF). 
However, only four of these cases had onset of 
symptoms within their R/LTCF.
Severe disease
Thirteen (7.7%) CDI cases were classified as severe 
disease using surveillance definitions. Nine of the 
13 had been admitted to hospital in the previous 
3 months. No patients with severe CDI had been 
admitted from an R/LTCF.
The 30-day mortality following diagnosis was 
3.6%. Of the 6 patients who died, four had been 
admitted to hospital within the past month, two 
had recurrent CDI and two had onset of symp-
toms in the community. All 6 cases had been pre-
scribed antibiotics in the last month. The mean 
age of these patients was 75.8 years, (95% CI: 
67.1–84.6), which was significantly greater than 
CDI patients who did not develop severe disease 
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Table 1:  Clostridium difficile infections patient characteristics
Survey variable
Number of cases 
(n = 168) Percentage
Age range 
2–20 10 6.0
21–40 22 13.1
41–60 30 17.9
61–80 59 35.1
80+ 47 28.0
Sex
Male 86 51.2
Female 82 48.8
Patient location at onset of symptoms
Hospital 98 58.3
Residential/long term care facility 4 2.4
Community 62 36.9
Not reported 4 2.4
Previous hospitalisation
Within the last month 86 51.2
Within last 1–3 months 33 19.6
More than 3 months ago 16 9.5
No previous hospitalisation 19 11.3
Not reported 14 8.3
Admission from residential/long term care facility
Within the last month 15 8.9
No previous residential/long term care admission 153 91.1
Is this episode a recurrence (within 8 weeks of onset of previous episode)?
Yes 20 11.9
No 135 80.4
Not reported 13 7.7
Antibiotic therapy in the last month
Yes 136 81.0
No 13 7.7
Not reported 19 11.3
Severity of disease
Intensive care admission for CDI 7 4.2
Colectomy due to CDI 0 0.0
Mortality within 30 days related to infection 6 3.6
No severe disease 91 54.2
Not reported 64 38.1
CDI Clostridium difficile infections.
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(62.1 years, 95% CI: 57.1–67.0). Due to the pres-
ence of significant co-morbidities it was difficult 
to ascertain whether the primary cause of death 
in these patients was CDI.
Ribotyping data
C. difficile isolates were obtained from 83 (81.4%) 
of 102 specimens submitted for culture. The preva-
lence of ribotypes detected is shown in Table 2. 
The most commonly isolated ribotype was UK 002 
(22.9%), and UK 014 was the 2nd most prevalent 
(13.3%). Ribotypes UK 014 and UK 020 are often 
combined due to difficulty distinguishing between 
their ribotyping patterns. The UK 014/020 group 
constituted 19.3% of isolates.
There were no isolates of ribotype UK 027, and 
only 1 isolate was ribotype UK 078. This case 
(a 46-year-old male) had onset of symptoms more 
than 48 hours after admission to hospital, and did 
not develop severe disease.
Ribotype UK244 was the 3rd most common 
ribotype circulating with 7 cases detected. Further 
detail on the cases infected with ribotype UK 244 
is presented in Table 3.
Discussion
The results of this snapshot give insight into the 
burden of disease as well as the prevalence of 
hypervirulent C. difficile strains in Queensland. 
In Queensland all public hospitals (n = 170) 
are serviced by Pathology Queensland or Mater 
Pathology laboratories, with consistent laboratory 
protocols, and data stored in a centralised data-
base. As a result we were able to identify all public 
hospital CDI cases during this time. In addition, 
with the support of five of the largest private 
facilities in the state, and their pathology pro-
viders, this study provided a detailed state-wide 
picture of the prevalence of cases, demographic 
and clinical risk factors and circulating ribotypes.
The study emphasised the importance of timely 
surveillance by infection control practitioners 
(ICPs). We were able to gather very useful infor-
mation with the support of ICPs, to confirm that 
CDI is not just a hospital issue in Queensland, 
with 37% (62/168) of cases developing symptoms 
in the community.
We believe previous admission to hospital may 
still play a role in cases with onset of symptoms 
in the community and residential care facilities. 
The majority of cases in this study developed 
Table 3:  Characteristics of patients infected with Clostridium difficile ribotype 244
Age (years) Sex Hospital type Onset of symptoms Resident Severity of disease
54 F Private Community No No severe disease
85 F Public Community No ICU admission
42 F Public Community No No severe disease
25 M Public Hospital No No severe disease
82 F Public Hospital No Died
88 F Public Hospital Yes Unknown
52 M Public Hospital No No severe disease
ICU Intensive care unit.
Table 2:  Prevalence of ribotypes detected 
during the study n = 83
Ribotype N % of isolates
UK 002 19 22.9
UK 014 11 13.3
UK 244 7 8.4
QX 014 WR AI-37 5 6.0
UK 056 5 6.0
UK 043 4 4.8
UK 020 3 3.6
QX 025 2 2.4
QX 150 WR 632 2 2.4
UK 014/020 2 2.4
UK 017 2 2.4
UK 049 2 2.4
UK 054 2 2.4
UK 070 2 2.4
Unique* 15 18.1
* Includes UK 005, UK 015/191, UK 018, UK 070, UK 
076, UK 078, UK 087, UK 126, QX 026 WR 404, QX 
029 WR 409, QX 033 WR AI-83, QX 072 WR 629, QX 
095 WR AI-34, QX 266 WR 637 and QX 291 WR 641.
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symptoms only after hospitalisation (98/168 58%). 
Of the 9 patients who had their onset within 
48 hours of hospital admission, five had had a 
previous hospital admission in the last month. 
Of the 62 cases who developed symptoms in the 
community, 27 (44%) had been admitted to a 
hospital in the previous month and 15 (24%) in 
the previous 1 to 3 months. Frequent movement 
of patients between hospital and the community 
may contribute to the challenge of determining 
the true place of exposure, making traditional 
classifications of healthcare versus community 
associated infection misleading.11
Thirteen of the 168 (7.7%) CDI cases were clas-
sified as severe. The 30-day mortality was 3.6%. 
However, due to the advanced age of the 6 patients 
who died, as well as the presence of co-morbidities, 
it was difficult to ascertain whether the primary 
cause of death in these patients was CDI.
Only 49% of cases had an isolate ribotyped. We 
believe this is still representative of circulating 
ribotypes, as there did not appear to be any par-
ticular hospitals or laboratories more likely to have 
their samples successfully typed. Unfortunately, 
we were not able to ribotype strains from all cases 
of severe disease. Clinicians should be reminded to 
notify ICPs of suspected cases of severe disease in a 
timely fashion, as they are best placed to liaise with 
laboratories to ensure typing occurs.
Of the 102 specimens obtained for culture, 83 were 
successfully cultured and ribotyped. Of those 
ribotyped the most frequently isolated ribotype 
was UK 002 (19/83, 22.9%), which has also been 
most commonly detected in other regions of the 
world, such as Southern Scotland,12 and Hong 
Kong where it has been associated with increased 
sporulation.13 Ribotype UK 014 was the 2nd most 
prevalent ribotype (13.3%). Ribotypes UK 014 
and UK 020 are often combined due to difficulty 
distinguishing between their ribotyping patterns. 
The UK 014/020 group constituted 19.3% of iso-
lates. This was concordant with a European study 
reporting a combined prevalence of 16%.14
There were no isolates of ribotype UK 027, 
which is known to have caused severe disease in 
North America and Europe.2 Only 1 isolate was 
ribotype UK 078, a community-associated strain 
with increased potential to cause severe disease.15 
However, this case (a 46-year-old male) had onset 
of symptoms more than 48 hours after admission 
to hospital, and did not develop severe disease. 
The link between the presence of hypervirulent 
strain type and severity of disease remains dif-
ficult to elucidate, although evidence for the 
importance of strain type as an independent 
risk factor is increasing.3 In the United States of 
America, the CDI epidemic saw the emergence 
of ‘hypervirulent’ strains in an older and sicker 
population, which made it challenging to deter-
mine whether the rise in severity was due to the 
pathogen, or due to other host factors such as age 
and co-morbidities.16
There has been Australia-wide interest in the 
prevalence of ribotype 244 – a recently described 
strain that appears to be closely related to 027, and 
which is possibly of similarly high virulence.17 In 
Australia, ribotype 244 was first detected by The 
University of Western Australia in specimens from 
a large Sydney hospital (personal communication, 
T Riley, 22 April 2013). Ribotype 244 has since 
been detected in several parts of Australia, and in 
New Zealand where it was associated with severe 
disease and community onset of infection.18,19
The risk of ribotype UK 244 in the Queensland 
population is unknown. Although in other 
Australian jurisdictions ribotype 244 has previ-
ously been reported to be a community ribotype 
associated with a high probability of severe 
disease, this was not uniformly the case in this 
Queensland study. Lim et al have recently pub-
lished a case-control study of 14 ribotype 244 
cases, matched by hospital locality and date of 
diagnosis to 24 controls; demonstrating a clini-
cally, but not statistically significant increase in 
severity and 30 day mortality.19
Further larger studies, incorporating a more 
geographically representative range of hospitals, 
may be required to determine the risk associ-
ated with this ribotype in Australia. In addition, 
regardless of ongoing efforts to monitor hospital 
infections,5 it would be useful for a continuous 
national passive surveillance program to be con-
sidered, with periodic ribotyping. This type of 
surveillance, such as that undertaken for nation-
ally notifiable conditions, would assist decision 
makers to determine the level of risk to the com-
munity, and plan public health interventions in 
a more timely fashion.
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